Welcome to our dedicated page for Gritstone bio news (Ticker: GRTS), a resource for investors and traders seeking the latest updates and insights on Gritstone bio stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Gritstone bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Gritstone bio's position in the market.
Gritstone Oncology (Nasdaq: GRTS), a biotechnology firm focused on cancer immunotherapy, will have its CEO Andrew Allen presenting at two investor conferences this September. The conferences include the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020, at 10:30 a.m. ET and the Cantor Virtual Global Healthcare Conference on September 17, 2020, at 9:20 a.m. ET. A live webcast will be available on their website, with an archived replay accessible for 30 days post-event.
Gritstone is developing next-gen cancer treatments through its innovative machine learning platform and neoantigen therapies.
Gritstone Oncology reported a net loss of $25.9 million for Q2 2020, up from $21.2 million in Q2 2019. Collaboration revenue decreased to $0.5 million from $1.2 million year-over-year. R&D expenses rose to $21.3 million, with general/admin costs at $5.3 million. Despite these financial challenges, Gritstone highlighted advancements in its immunotherapy programs, GRANITE and SLATE, showcasing strong T cell responses and initiating further clinical trials. Cash reserves stood at $92.9 million, down from $128.8 million at the end of 2019.
Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology firm, announced an investor teleconference for July 13, 2020, at 8:00 a.m. ET to discuss data from its Phase 1 studies of immunotherapy candidates GRANITE and SLATE. The event will feature Daniel Catenacci, M.D., as a principal investigator. The call will be accessible via phone and webcast, with an archived replay available for 30 days. Gritstone focuses on developing cancer immunotherapies by leveraging machine learning to predict tumor-specific neoantigens from biopsies.
Gritstone Oncology (Nasdaq: GRTS) has appointed Jean-Charles Soria, M.D., Ph.D., CEO of Gustave Roussy Cancer Center, to its scientific advisory board. His extensive experience in oncology, including his previous role at AstraZeneca, is expected to enhance Gritstone's development programs. Dr. Soria's focus will be on utilizing Gritstone's proprietary AI platform, Gritstone EDGE™, to maximize the company's cancer immunotherapy potential. This leadership change reflects a commitment to advancing the treatment landscape for solid tumors, particularly as its lead programs near Phase 1 trial completion.
Gritstone Oncology (Nasdaq: GRTS) reported Q1 2020 financial results, posting a net loss of $26.2 million compared to $18.0 million in Q1 2019. The company generated $1.3 million in collaboration revenue, unchanged from the previous year. R&D expenses rose to $22.5 million, driven by increased personnel and operational costs. Gritstone highlighted promising early clinical data from Phase 1 trials for its GRANITE and SLATE therapies, aiming to initiate Phase 2 studies soon. As of March 31, 2020, cash reserves stood at $109.9 million, down from $128.8 million at year-end 2019.
Summary not available.